# Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection

> **NCT04447235** · PHASE2 · TERMINATED · sponsor: **Instituto do Cancer do Estado de São Paulo** · enrollment: 77 (actual)

## Conditions studied

- Cancer
- COVID
- Coronavirus Infection

## Interventions

- **DRUG:** Placebo
- **DRUG:** Ivermectin
- **DRUG:** Losartan

## Key facts

- **NCT ID:** NCT04447235
- **Lead sponsor:** Instituto do Cancer do Estado de São Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-23
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** futility analysis has demonstrated no difference between arms
- **Last updated:** 2022-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04447235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04447235, "Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04447235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*